Tonix Pharmaceuticals 株価情報 (NASDAQ: TNXP)

最新ニュース Tonix Pharmaceuticals (NASDAQ:TNXP) 株価情報

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

News

Pre-Market Outlook

Markets

Movers

AYRO

CLDI

CLNN

GDHG

GOOGL

MREO

OBLG

ORCL

PETS

PIXY

SRFM

THMO

TNXP

WLGS

オラクル・コーポレーション (NYSE:ORCL) の株価は、同社が第4四半期決算を発表した後、本日のプレマーケット取引で急騰しました。オラクルは自社の2021年4月～6月期決算において、予想を下回る決算を発表しました。同社は、アルファベット（Alphabet Inc）（NASDAQ:GOOGL）（NASDAQ:GOOG）のGoogle Cloudと提携することも発表しました。

オラクルの株価9%上昇の理由

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals Holding Corp

https://www.reuters.com/world/uk/uk-detects-two-more-cases-new-mpox-variant-2024-11-04/#:~:text=LONDON%2C%20Nov%204%20(Reuters),to%20the%20population%20remained%20low.

Macro Notification

General

AEMD

CMRX

GOVX

MRNA

VRAX

'UK detects two more cases of new mpox variant' - Reuters

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801: Says New Data Show Tolerability And No Evidence Of Spreading To Blood Or Tissues Even At High Doses Of Tonix's Attenuated Live-virus, Minimally Replicating Vaccine Candidate Tnx-801 In Immunocompromised Animals

APDN

BWVI

WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has risen 179.25% since its last report. The company recently reported that it has 8.29 million shares sold short, which is 5.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729619117_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 2.12%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(TNXP) - Analyzing Tonix Pharmaceuticals's Short Interest

<a href="https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms">https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms</a>
An infection with the new mpox variant clade 1b has been detected in Germany for the first time, the Robert Koch Institute health authority said on Tuesday. &nbsp;

Biotech

Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times

WIIM

Tonix Pharmaceuticals shares are trading higher after the company announced it received its first contract payment from the U.S. Department of Defense.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, received its first payment from the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense (DoD), to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. The previously announced award from DTRA is for up to $34 million over five years.

Contracts

Tonix Pharmaceuticals Receives First Contract Payment From U.S. Department Of Defense For Accelerated Development Of Broad-Spectrum Antivirals With The Defense Threat Reduction Agency; The Previously Announced Award From DTRA Is For Up To $34M Over 5-Years

Tonix Pharmaceuticals shares are trading higher after the company announced it submitted an NDA for TNX-102 SL to the FDA for fibromyalgia treatment. The non-opioid analgesic showed significant pain reduction in Phase 3 studies and received fast-track designation.

Tonix Pharmaceuticals Submits NDA For TNX-102 SL To FDA For Fibromyalgia Treatment; Non-Opioid Analgesic Shows Significant Pain Reduction In Phase 3 Studies And Receives Fast Track Designation

Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are trading higher by 1.18% to $0.14 during Tuesday&#8217;s session after the company secured a $34 million DOD research <a href="https://www.benzinga.com/pressreleases/24/10/g41226812/tonix-pharmaceuticals-announces-ai-collaboration-with-x-chem-to-develop-broad-spectrum-antivirals">collaboration contract</a> with X-Chem.
What To Know: Tonix Pharmaceuticals announced a research collaboration with X-Chem to accelerate the development of its TNX-4200 oral broad-spectrum antiviral program. The collaboration will leverage X-Chem&#8217;s AI and machine learning technologies to optimize the drug's properties, safety and pharmacokinetics. 
The company says TNX-4200 focuses on oral CD45 phosphatase inhibitors with broad-spectrum antiviral potential, supported by a $34 million contract from the U.S. Department of Defense&#8217;s Defense Threat Reduction Agency (DTRA). 
Tonix says the DTRA funding will help advance the TNX-4200 program through key development stages, including an IND submission and a first-in-human Phase 1 trial. Tonix is meanwhile utilizing its R&amp;D facilities in Maryland for the project.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41222716/as-florida-prepares-for-one-of-deadliest-hurricanes-here-are-some-potential-stock-winners-and-lo">As Florida Prepares For One Of Deadliest Hurricanes, Here Are Some Potential Stock Winners And Losers From Milton Threat</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP has a 52-week high of $22.14 and a 52-week low of $0.12.

Why Tonix Pharmaceuticals (TNXP) Stock Is Moving

Tonix Pharmaceuticals shares are trading higher after the company secured a $34 million DOD research collaboration contract with X-Chem.

Tonix Pharmaceuticals Enters AI And ML Research Collaboration With X-Chem To Develop Broad-Spectrum Antivirals

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has entered into an AI and ML research collaboration with X-Chem, Inc. (X-Chem), a leader in small molecule drug discovery, to accelerate development of Tonix's oral broad-spectrum antivirals.
Tonix's TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families. As previously disclosed, Tonix entered into a contract with the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA) for up to $34 million to advance the development of Tonix's TNX-4200 broad-spectrum oral antiviral program for medical countermeasures, including an Investigational New Drug (IND) submission and a first-in-human Phase 1 clinical study.
"We are excited to enter into this research collaboration with X-Chem, which we believe will expand our capabilities, and deepen our understanding of host-targeted small molecule therapeutics for a variety of targets," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "With the support of X-Chem's drug discovery AI/ML technology, we expect to optimize the physicochemical properties, pharmacokinetics, and safety attributes of our drug candidates."
"We are excited to partner with Tonix in their pursuit of such important programs in human health, at the intersection of laboratory and in silico technology. This collaboration highlights how integrative work continues to leverage the creation of target-specific high-quality data to drive AI drug discovery," said Erin Davis, Ph.D., Chief Technology Officer of X-Chem."
The DTRA contract awarded to Tonix is expected to help fund and accelerate the development of the Company's lead oral host-directed TNX-4200 broad-spectrum antiviral program. The TNX-4200 program aims to reduce viral load and to allow the adaptive immune system to alert the other arms of the immune system to mount a protective response. Tonix plans to leverage previous research on phosphatase inhibitors to optimize lead compounds for therapeutic intervention of biothreat agents.
For the oral broad-spectrum antiviral programs, including TNX-4200, Tonix is utilizing its state-of-the-art research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility at its research and development center (RDC) located in Frederick, Md., as well as experienced personnel in-house. The RDC is located in Maryland's ‘I-270 biotech corridor' and is close to the center of the U.S. biodefense research community.

Government

Regulations

Tonix Pharmaceuticals Secures $34M DOD Contract, Collaborates with X-Chem on Antiviral Research to Boost Development of Oral Antivirals Using AI and ML

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are trading higher Friday after the company announced the United States Patent and Trademark Office&nbsp;granted a patent covering the subcutaneous delivery of Zembrace Symtouch for treating migraines.
The Details: Issued on September 24, the patent entitled &#8216;Pharmaceutical Composition for Treating Migraine&#8217; is anticipated to provide protection into 2036.
This comes after the company launched a campaign called &#8216;Does Your Migraine Pill Work Every Time?&#8217; with the goal of informing healthcare providers and consumers about the advantages of non-oral migraine medications.
How To Buy Tonix Pharmaceuticals Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
See Also:<a href="https://www.benzinga.com/markets/cannabis/24/09/41033009/can-novo-nordisks-weight-loss-drug-ozempic-help-stem-the-devastating-addiction-crisis-new-resear"> Can Novo Nordisk&#8217;s Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes</a>
TNXP Price Action: At the time of writing, Tonix shares are trading 17.2% higher at 16 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Akava Photo from Pixabay

What's Going On With Tonix Pharmaceuticals Stock Friday?

Tonix Pharmaceuticals shares are trading higher after the company announced the issuance of a US patent covering the subcutaneous delivery of Zembrace Symtouch for treating migraines, with market exclusivity expected into 2036.

Tonix Pharmaceuticals Announces Issuance Of U.S. Patent Covering The Subcutaneous Delivery Of FDA-approved Zembrace Symtouch To Treat Migraines; New Patent Expected To Provide Market Exclusivity Into 2036

<a href="https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.">https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.</a>
&nbsp;
Los Angeles County health officials are reporting a significant uptick in mpox cases, prompting renewed calls for vaccination among&nbsp;high-risk&nbsp;groups.
The County's Department of Public Health announced that 52 mpox cases were reported in the past four weeks, compared to 24 in the previous&nbsp;four-week&nbsp;period.&nbsp;
About 70% of new cases in the last six months occurred in&nbsp;unvaccinated&nbsp;individuals.
Health officials strongly recommend vaccination for several high-risk groups, including men and transgender people who have sex with men or transgender persons, persons of any gender or sexual orientation who have sex or intimate physical contact with others in association with large public events or engage in commercial and/or transactional sex, and those living&nbsp;with&nbsp;HIV.
"Vaccination is an important tool in preventing the spread of mpox," the County health department said in a statement. The two-dose JYNNEOS vaccine is available at pharmacies for insured residents and at Los Angeles County Department of Public Health Clinics for free&nbsp;without&nbsp;appointments.
Officials advise residents to practice safe sex, limit sexual partners, and avoid intimate contact with anyone showing mpox symptoms, which include rash, fever, and swollen lymph nodes. Additional prevention measures include asking partners about symptoms, reducing the number of partners, and proper use of condoms&nbsp;and&nbsp;gloves.
The County emphasizes the importance of testing for those who develop symptoms consistent with mpox. The Department of Public Health is collaborating with healthcare providers and community organizations to intensify surveillance, contact tracing, and outbreak investigations to&nbsp;curb&nbsp;transmission.
Mpox, previously referred to as Monkeypox, is mainly spread through close physical contact. Residents seeking more information can visit<a href="http://ph.lacounty.gov/mpox"> ph.lacounty.gov/mpox</a> or call the Department of Public Health Call Center&nbsp;at&nbsp;1-833-540-0473.

Macro Economic Events

Economics

'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now

<a href="https://www.youtube.com/watch?v=ZFW3ONApp4w" title="https://www.youtube.com/watch?v=ZFW3ONApp4w">https://www.youtube.com/watch?v=ZFW3ONApp4w</a>

Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa

-Reuters Citing Senior Administration Official

President Biden Will Announce Donation Of 1M MPox Vaccine Doses, At Least $500M To African Countries To Support Their Response To Outbreak

CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic

Warning: TNXP is at high risk of performing badly

Tonix Pharmaceuticals (TNXP) presented data in an oral presentation at the World Vaccine Congress-Europe 2024, held October 28-31, 2024 in Barcelon...

Tonix Pharmaceuticals presents data on TNX-801 at World Vaccine Congress

Tonix Pharmaceuticals (TNXP) announced that it has entered into a sponsored research agreement with the Kenya Medical Research Institute, KEMRI, to...

Tonix Pharmaceuticals announces research agreement with KEMRI

An update from Tonix Pharma ( ($TNXP) ) is now available. Tonix Pharmaceuticals has partnered with the Kenya Medical Research Institute to launch a...

Tonix Pharma Partners for Vaccine Clinical Trial

Tonix Pharma ( ($TNXP) ) has issued an update. Tonix Pharmaceuticals Holding Corp. has unveiled new data from a manuscript showing promising result...

Tonix Pharma Unveils Promising TNX-1700 Cancer Data

Screenshot 2024-09-30 at 9.13.36 PM

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-18 at 12.30.33 AM

BVNKF

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Untitled design - 2024-09-04T162950.621

As Research Into Pain Accelerates, A Newly Recognized Type Of Pain Comes To The Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL

Screenshot 2024-08-23 at 3.09.59 AM

Modern Twist To Centuries-Old Smallpox Vaccine Could Be Poised To Combat Deadly Mpox Strain As WHO Declares Global Emergency

Screenshot 2024-08-01 at 5.06.20 PM

FDA Recognizes Fibromyalgia As A &#39;Serious Condition&#39; And Fast-Tracks New Drug Candidate

Screenshot 2024-07-23 at 10.19.53 PM

Beyond &#34;One Bug, One Drug&#34; – Tonix Pharmaceuticals Secures Up To $34 Million In Funding From U.S. Department Of Defense To Develop Broad-Spectrum Antiviral

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-02-24 at 12.03.42 AM

ABBV

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions

AI Security, "Netflix of China", Healthcare Breakthroughs, Pure Play on $31 Billion Watch Market: iQIYI, TNXP, REGRF, AITX; Leaders Report Latest Advances

Health Care

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals

Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)

Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA)

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Tonix Pharmaceuticals to Present at BIO-Europe® 2024

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya

AITX

CSE:NEWS

REGRF

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cyclo Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

HCW Biologics

iBio

Kairos Pharma

MEI Pharma

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Nanoviricides

NeuroBo Pharmaceuticals, Inc. - Common Stock

NeuroBo Pharmaceuticals

Onconetix

BiomX

Pieris Pharmaceuticals, Inc. - Common Stock

Pieris Pharmaceuticals

PharmaCyte Biotech

Palatin Techs

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Spruce Biosciences

Synlogic

Tenax Therapeutics

Unity Biotechnology

Alliance Global Partners

Dawson James

Noble Capital Markets

オラクル・コーポレーション (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) の株価は、同社が<a href="https://www.benzinga.com/news/earnings/24/06/39280057/oracle-misses-q4-earnings-stock-surges-on-booming-ai-demand-openai-contract-partnership-with-google">第4四半期決算を発表した後、本日のプレマーケット取引で急騰しました。</a>
オラクルは自社の2021年4月～6月期決算において、予想を下回る決算を発表しました。同社は、アルファベット（Alphabet Inc）（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>）（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>）のGoogle Cloudと提携することも発表しました。
プレマーケット取引でオラクルの株は前場で135.00ドルに急騰しました。
以下は、プレマーケット取引で動いている他の銘柄です。
<h3 class="wp-block-heading">株価最大上昇</h3>
<ul>
<li>本日のプレマーケット取引でGolden Heaven Group Holdings Ltd（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>）の株は0.3049ドル（70.3%高）に上昇しました。</li>
<li>本日のプレマーケット取引でWANG＆amp;LEE GROUP, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>）の株は0.8760ドル（43.1%高）に上昇し、火曜日には16%上昇していました。</li>
<li>本日のプレマーケット取引でSurf Air Mobility Inc.（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>）の株は0.3860ドル（38%高）となりました。 Surf Air MobilityはブラジルのCessna Caravanを運営するAsta社に電動パワートレインを供給する合意を締結しました。</li>
<li>本日のプレマーケット取引でBeamr Imaging Ltd.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMR#NASDAQ">BMR</a>）の株は5.64ドル（28.2%高）に上昇しました。 Beamrは、同社のクラウドソリューションが現在、Oracle Cloud Marketplaceで利用可能であると述べています。</li>
<li>本日のプレマーケット取引でCastellum, Inc.（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>）の株は0.2410ドル（24.9%高）に上昇しました。</li>
<li>火曜日にTrianが同社に出資しているとの報告に続き、本日のプレマーケット取引でRentokil Initial plc（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>）の株は30.01ドル（11.5%高）に上昇しています。</li>
<li>本日のプレマーケット取引でThe Aaron&#8217;s Company, Inc.（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAN#NYSE">AAN</a>）の株は8.88ドル（10.9%高）に上昇しました。</li>
<li>本日のプレマーケット取引でMereo BioPharma Group plc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>）の株は3.90ドル（10.8%高）に上昇しました。UltragenyxとMereoは、第2/3部分の第2相Orbit試験の14か月の結果を発表しました。</li>
<li>本日のプレマーケット取引でAyro, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>）の株は0.8991ドル（9.6%高）に上昇しました。</li>
</ul>
<h3 class="wp-block-heading">株価最大下落</h3>
<ul>
<li>ナスダックは、ThermoGenesis Holdings, Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>）の株がプレマーケット取引で49.8%下落し0.2691ドルに低下したことを受け、同社のリスティング維持要請を拒否しました。同社の株は2024年6月17日の取引開始時に取引が停止されます。</li>
<li>火曜日には4%下落していたことを受け、本日のプレマーケット取引でClene Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>）の株は0.31ドル（24.7%下落）に低下しました。</li>
<li>本日のプレマーケット取引でTonix Pharmaceuticals Holding Corp（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>）の株は1.61ドル（24.4%下落）に下落しました。同社は株式の公開募集を発表しました。</li>
<li>火曜日の取引で17%上昇した後、本日のプレマーケット取引でKWESST Micro Systems Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>）の株は0.7965ドル（21.9%下落）に下落しました。KWESST Micro Systemsは最近、ソフトウェア開発サービスに関するThales Canada社から最大4800万カナダドル相当のサブ契約を受けました。</li>
<li>火曜日には5%上昇していたことを受け、本日のプレマーケット取引でShiftPixy, Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>）の株は1.32ドル（14.3%下落）に低下しました。</li>
<li>火曜日には5%下落していたことを受け、本日のプレマーケット取引でOblong, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>）の株は0.1723ドル（14.2%下落）に低下しました。Obglongは最近、Dwellwell Analyticsを取得するための拘束力のない意向書に署名しました。</li>
<li>火曜日には混合の四半期決算を発表し、本日のプレマーケット取引でPetMed Express, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>）の株は4.06ドル（13.8%下落）に低下しました。同社は、四半期決算において難しいマクロ環境と業界の動向が結果に悪影響を及ぼしたと述べています。</li>
<li>火曜日には13%上昇した後、本日のプレマーケット取引でmF International Limited（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>）の株は0.99ドル（13%下落）に低下しました。</li>
<li>火曜日には32%上昇した後、本日のプレマーケット取引でCalidi Biotherapeutics, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NASDAQ">CLDI</a>）の株は0.2370ドル（12.2%下落）に低下しました。Calidi Biotherapeuticsは最近、肺がんおよび転移性固形腫瘍のためのCalidiのRTNovaウイロセラピーを進めるためにSIGA Technologies社と協力することを発表しました。</li>
<li>火曜日に23%下落した後、本日のプレマーケット取引でBig Tree Cloud Holdings Limited（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>）の株は2.45ドル（11.9%下落）に低下しました。Big Tree Cloudは最近、Plutonian Acquisition Corp とのビジネスコンビネーションを完了したことを発表しました。</li>
</ul>

Comments

Tonix Pharmaceuticals

ニュース

最新ニュース Tonix Pharmaceuticals (NASDAQ:TNXP) 株価情報

水曜日, 6 12, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル